Inhaltsbereich
| 13 Einträge |
Seite 1 / 1
 Druckansicht
|
| FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. |
| Kaczirek K, Ciuleanu TE, Vrbanec D, Marton E, Messinger D, Liegl-Atzwanger B, Wrba F, Knittelfelder R, Lindner E, Zielinski CC, Streubel B, Brodowicz T |
| Clinical colorectal cancer. 2014 Dec 24. pii: S1533-0028(14)00134-0. doi: 10.1016/j.clcc.2014.12.003 |
| PMID: 25666295 |
| Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. |
| Brodowicz T, Lang I, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Petruzelka L, Eniu A, Anghel R, Koynov K, Vrbanec D, Pienkowski T, Melichar B, Spanik S, Ahlers S, Messinger D, Inbar MJ, Zielinski C |
| British journal of cancer. 2014 Sep 30. pii: bjc2014504. doi: 10.1038/bjc.2014.504. pmc: PMC4260030 |
| PMID: 25268370 |
| FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. |
| Brodowicz T, Ciuleanu TE, Radosavljevic D, Shacham-Shmueli E, Vrbanec D, Plate S, Mrsic-Krmpotic Z, Dank M, Purkalne G, Messinger D, Zielinski CC |
| Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013 Apr 4. pii: mdt116. doi: 10.1093/annonc/mdt116 |
| PMID: 23559149 |
| Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. |
| Zielinski C, Lang I, Beslija S, Kahan Z, Inbar MJ, Stemmer SM, Anghel R, Vrbanec D, Messinger D, Brodowicz T |
| British journal of cancer. 2015 Dec 10. pii: bjc2015419. doi: 10.1038/bjc.2015.419 |
| PMID: 26657657 |
| A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6 cetuximab versus FOLFIRI cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC). |
| Ciuleanu TE, Kurteva G, Ocvirk J, Beslija S, Koza I, Papamichael D, Vrbanec D, Brodowicz T, Scheithauer W, Zielinski CC |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Jan 1. pii: 10.1200/jco.2008.26.15_suppl.4032 |
| PMID: 27949288 |
| Time interval between final protocol approval (FPA) and inclusion of the first patient into randomized clinical trials (RCTs) performed by the Central European Cooperative Oncology Group (CECOG): A 10-year experience. |
| Brodowicz T, Steiner I, Beslija S, Ciuleanu TE, Inbar M, Krzakowski M, Kahan Z, Tzekova V, Vrbanec D, Zielinski CC |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 May 27. pii: 10.1200/jco.2009.27.15_suppl.6546 |
| PMID: 27964062 |
| Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6 cetuximab (FX C) or FOLFIRI cetuximab (FF C): The CECOG/CORE1.2.001 trial. |
| Koza I, Wrba F, Vrbanec D, Ocvirk J, Ciuleanu TE, Beslija S, Papamichael D, Messinger D, Zielinski CC, Brodowicz T |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 1. pii: 10.1200/jco.2009.27.15_suppl.4055 |
| PMID: 27961587 |
| Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D mutated metastatic colorectal cancer (mCRC)? A meta-analysis of 54 cases. |
| Heinemann V, Reinacher-Schick A, Stintzing S, Giessen CA, Tannapfel A, Laubender RP, Brodowicz T, Knittelfelder R, Vrbanec D, Schmiegel W, Modest DP, Zielinski C |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Apr 30. pii: 10.1200/jco.2012.30.4_suppl.511 |
| PMID: 27983404 |
| Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC). |
| Ciuleanu T, Nikolic V, Shmueli E, Vrbanec D, Plate S, Krmpotic ZM, Dank M, Purkalne G, Brodowicz T, Zielinski C |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Apr 29. pii: 10.1200/jco.2011.29.4_suppl.494 |
| PMID: 27985536 |
| Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC). |
| Ciuleanu T, Nikolic V, Shmueli E, Vrbanec D, Plate S, Krmpotic ZM, Dank M, Purkalne G, Brodowicz T, Zielinski C |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Jan 1. pii: 10.1200/jco.2011.29.15_suppl.3580 |
| PMID: 28020239 |
| Biosimilars in the Treatment of Breast Cancer. |
| Balic M, Bartsch R, Bauernhofer T, Vrbanec D, Vrdoljak E |
| Breast care (Basel, Switzerland). 2017 Jun 13. doi: 10.1159/000477926. pii: brc-0012-0192. pmc: PMC5527174 |
| PMID: 28785188 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
| Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
| The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
| PMID: 29146401 |
| FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. |
| Brodowicz T, Ciuleanu TE, Radosavljevic D, Shacham-Shmueli E, Vrbanec D, Plate S, Mrsic-Krmpotic Z, Dank M, Purkalne G, Messinger D, Zielinski CC |
| Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Dec 4. pii: S0923-7534(19)36658-X. doi: 10.1093/annonc/mdt116 |
| PMID: 32018612 |
| 13 Einträge |
Seite 1 / 1
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
